Business Description
Blueprint Medicines Corp
NAICS : 325412
SIC : 2834
ISIN : US09627Y1091
Compare
Compare
Traded in other countries / regions
BPMC.USA2L9.Germany0HOJ.UK IPO Date
2015-04-30Description
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates BLU-285, which targets KIT Exon 17 mutants and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. Its other drug candidate is BLU 554 FOR Advanced Hepatocellular Carcinoma, and BLU-667 for Ret Mutations, Fusions, and Predicted Resistant Mutants.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 3.03 | |||||
| Equity-to-Asset | 0.28 | |||||
| Debt-to-Equity | 0.77 | |||||
| Debt-to-EBITDA | -0.47 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -0.95 | |||||
| Beneish M-Score | -2.49 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 35 | |||||
| 3-Year EBITDA Growth Rate | -5.8 | |||||
| 3-Year EPS without NRI Growth Rate | -8.7 | |||||
| 3-Year FCF Growth Rate | -12 | |||||
| 3-Year Book Growth Rate | -3.1 | |||||
| Future 3-5Y Total Revenue Growth Rate | -3.92 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 63.04 | |||||
| 9-Day RSI | 54.09 | |||||
| 14-Day RSI | 50.54 | |||||
| 6-1 Month Momentum % | 8.63 | |||||
| 12-1 Month Momentum % | -25.83 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.8 | |||||
| Quick Ratio | 4.7 | |||||
| Cash Ratio | 4.28 | |||||
| Days Inventory | 738.1 | |||||
| Days Sales Outstanding | 43.72 | |||||
| Days Payable | 216.37 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -6.8 | |||||
| Shareholder Yield % | -3.61 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 94.08 | |||||
| Operating Margin % | -233.26 | |||||
| Net Margin % | -245.62 | |||||
| ROE % | -105.43 | |||||
| ROA % | -43.79 | |||||
| ROIC % | -147.33 | |||||
| ROC (Joel Greenblatt) % | -447.93 | |||||
| ROCE % | -47.47 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 13.35 | |||||
| PB Ratio | 9.79 | |||||
| Price-to-Tangible-Book | 9.79 | |||||
| EV-to-EBIT | -5.05 | |||||
| EV-to-EBITDA | -5.21 | |||||
| EV-to-Revenue | 11.61 | |||||
| EV-to-Forward-Revenue | 8.38 | |||||
| EV-to-FCF | -5.07 | |||||
| Price-to-Net-Current-Asset-Value | 193.15 | |||||
| Earnings Yield (Greenblatt) % | -19.8 |
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:BPMC
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Blueprint Medicines Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 225.615 | ||
| EPS (TTM) ($) | -9.22 | ||
| Beta | 0.49 | ||
| Volatility % | 44.85 | ||
| 14-Day RSI | 50.54 | ||
| 14-Day ATR ($) | 1.820041 | ||
| 20-Day SMA ($) | 50.929 | ||
| 12-1 Month Momentum % | -25.83 | ||
| 52-Week Range ($) | 37.82 - 68.63 | ||
| Shares Outstanding (Mil) | 60.66 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Blueprint Medicines Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Blueprint Medicines Corp Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Blueprint Medicines Corp Frequently Asked Questions
What is Blueprint Medicines Corp(BPMC)'s stock price today?
The current price of BPMC is $50.22. The 52 week high of BPMC is $68.63 and 52 week low is $37.82.
When is next earnings date of Blueprint Medicines Corp(BPMC)?
The next earnings date of Blueprint Medicines Corp(BPMC) is 2023-11-01 Est..
Does Blueprint Medicines Corp(BPMC) pay dividends? If so, how much?
Blueprint Medicines Corp(BPMC) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers